GLPG2534 / Galapagos - LARVOL DELTA

IRAK4 inhibition dampens pathogenic processes driving inflammatory skin diseases. (PubMed, Sci Transl Med) - "Here, we profiled a selective IRAK4 inhibitor, GLPG2534, in an extensive panel of models of inflammatory skin diseases, translationally expanding evidence from in vitro to in vivo and from mouse to human...Furthermore, disease activity in murine models of skin inflammation (IL-23-, IL-33-, imiquimod-, and MC903-induced) was markedly dampened by IRAK4 inhibition...Over the variety of models used, IRAK4 inhibition consistently affected central mediators of psoriasis (IL-17A) and atopic dermatitis (IL-4 and IL-13). Overall, our data highlight IRAK4 as a central player in skin inflammatory processes and demonstrate the potential of IRAK4 inhibition as a therapeutic strategy in chronic inflammatory skin diseases."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Psoriasis • IL13 • IL17A • IL1R1 • IL23A • IL33 • IL4 • IRAK4

IRAK4 drives pathogenic processes in inflammatory skin diseases (ESDR 2022) - "Here, we profiled a novel, selective IRAK4 inhibitor, GLPG2534, in an extensive series of in vitro, ex vivo, and in vivo models of inflammatory skin diseases (ISD)...Furthermore, disease activity in murine models of psoriasis and atopic dermatitis (AD) skin inflammation (Il-23-, Il-33-, imiquimod- and MC903-induced) was markedly dampened by IRAK4 inhibition...The variety of models highlighted IRAK4 as central mediator of psoriasis and atopic dermatitis by regulating cytokines (e.g. IL-17A, IL-22, IL-23, IL-4, IL-13, IL-5, TNF-α), chemoattractant chemokines (e.g. CXCL8, CXCL5, MCP1) and antimicrobial peptides (e.g. S100A7, DEFB4A). Overall, our data demonstrate the potential of IRAK4 inhibition as a therapeutic strategy in ISD."

Atopic Dermatitis • Dermatitis • Dermatology • Inflammation • Psoriasis • CXCL5 • CXCL8 • IL13 • IL17A • IL1R1 • IL22 • IL23A • IL33 • IL4 • IL5 • IRAK4 • TNFA